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Abstract 1 
Cytokine storm can result from cancer immunotherapy or certain infections, including 2 
COVID-19. Though short-term immune-related adverse events are routinely described, 3 
longer-term immune consequences and sequential immune monitoring are not as well 4 
defined. In 2006, six healthy volunteers received TGN1412, a CD28 superagonist 5 
antibody, in a first-in-man clinical trial and suffered from cytokine storm. After the initial 6 
cytokine release, antibody effect-specific immune monitoring started on Day+10 and 7 
consisted mainly of evaluation of dendritic cell and T-cell subsets and 15 serum 8 
cytokines at 21 time-points over two years. All patients developed problems with 9 
concentration and memory; three patients were diagnosed with mild-to-moderate 10 
depression. Mild neutropenia and autoantibody production was observed intermittently. 11 
One patient suffered from peripheral dry gangrene, required amputations, and had 12 
persistent Raynaud’s phenomenon. Gastrointestinal irritability was noted in three 13 
patients and coincided with elevated γδT-cells. One had pruritus associated with 14 
elevated IgE levels, also found in three other asymptomatic patients. Dendritic cells, 15 
initially undetectable, rose to normal within a month. Naïve CD8+ T-cells were 16 
maintained at high levels whereas naïve CD4+ and memory CD4+ and CD8+ T-cells 17 
started high but declined over two years. T-regulatory cells cycled circannually and were 18 
normal in number. Cytokine dysregulation was especially noted in one patient with 19 
systemic symptoms. Over a two-year follow-up, cognitive deficits were observed in all 20 
patients following TGN1412 infusion. Some also had signs or symptoms of 21 
psychological, mucosal or immune dysregulation. These observations may discern 22 
immunopathology, treatment targets, and long-term monitoring strategies for other 23 
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Significance:  1 
TGN1412 CD28 super-agonist antibody caused a cytokine storm in a first-in-man trial in 2 
2006. Here, the detailed two-year clinical and immune-monitoring is described providing 3 
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Introduction 1 
Antibody or cell-based immunotherapeutics for cancer carry inherent risks of 2 
bystander immune activation, in addition to the effects of treating the intended tumor 3 
target [1-5]. The most severe of these immune-related adverse events (irAEs) are 4 
cytokine release syndrome (CRS) and neurotoxicity, most prominently described in 5 
patients treated with CAR-T-cells [6-11]. Treatment for CRS and associated 6 
neurotoxicity primarily targets IL-6, likely arising from monocytes or activated 7 
endothelium [1, 6, 11-17]. The site of cell activation is unclear, and may depend on 8 
disease burden, treatment target or how CRS is induced; antibody and cell therapies 9 
target tumor sites whereas infections, such as SARS-CoV-2 causing COVID-19, target 10 
points of pathogen entry, e.g. mucosal sites of the nasopharynx, lung and 11 
gastrointestinal tract [1, 11-19]. Immune checkpoint blockade induces irAEs during 12 
short-term follow-up of some patients with cancer, though robust immune biomarkers 13 
correlating with adverse effects of therapy are still being investigated [1, 4, 7, 20-25]. 14 
For long-term survivors who received immunotherapy or following CRS, immune 15 
monitoring is not yet standard of care, despite evidence that such patients may continue 16 
to experience secondary effects of treatment and irAEs [1, 3]. 17 
In 2006, a superagonist anti-CD28 humanized monoclonal antibody (TGN1412) 18 
was infused into six healthy young male volunteers in a first-in-man clinical trial [26]. 19 
The antibody had specificity for the C’’D loop of the CD28 glycoprotein and had the 20 
unique capacity to activate T-cells solely through CD28 (signal 2) without the usual 21 
ligation of the T-cell receptor (signal 1) [27]. All six volunteers suffered from CRS, first 22 
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clinical studies was for selective T-regulatory cell (Treg) expansion, without cytokine 1 
release, the first effects observed in humans were those of cytokine storm. Patients 2 
displayed early high TNF-α release within an hour of infusion. This was associated with 3 
fever, delirium, nausea, vomiting and diarrhea, multi-organ failure (starting with the lung 4 
and rapidly progressive hypoxemia), disseminated intravascular coagulation, and a 5 
discrete absence of T-cells and monocytes from the peripheral blood [26]. The acute 6 
effects of the TGN1412-induced cytokine storm and the first 30 days of follow-up have 7 
already been reported [26]. Herein, we present the clinical and linked immunological 8 
data from 10 days sequentially to two years following TGN1412 infusion. All patients 9 
survived; dysfunction in cognitive, psychological, gastrointestinal, integumentary, and 10 
immune regulatory systems persisted for years following the event. We believe that the 11 
features described herein may help to identify the immunopathology of similar illnesses, 12 
such as irAEs and CRS due to other immunotherapies (e.g. checkpoint inhibitors, CAR-13 
T-cells) or COVID-19 [4, 18, 19], and to inform discussions on the type and length of 14 
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Materials and Methods 1 
 2 
Clinical trial 3 
TGN1412 was produced by TeGenero AG (Wϋrzberg, Germany), manufactured 4 
by Boehringer Ingelheim (Germany), and the clinical trial was conducted by the contract 5 
research organization, PAREXEL International (Waltham, MA, USA) in their leased UK 6 
clinical trial site at Northwick Park Hospital, London, UK. Details of the clinical trial and 7 
the first 30 days of clinical follow-up have been reported [26]. The patients presented 8 
herein as A, B, C, D, E and F correlate with those previously identified as patients 2, 1, 9 
5, 6, 4 and 3, respectively [26]. None of the authors of this work were involved with the 10 
conduct of the clinical trial or any of the pre-clinical testing of TGN1412.  11 
 12 
Patients and sources of data 13 
All six patients were followed clinically (off-trial) and assessed as a cohort 14 
following the serious adverse event (SAE). Overall care and immune monitoring was 15 
coordinated and interpreted by the lead clinician (NP) who made appropriate referrals to 16 
subspecialists (CJM, MH, NA) or requests for specific immune monitoring tests as 17 
determined by clinical need. From six months post-event, all patients were assessed in 18 
a specialist cognitive disorders clinic by an expert neurologist (CJM) and psychiatrist 19 
(MH). All patient blood samples were anonymized and the scientists performing 20 
immunologic tests were not aware of clinical symptoms, signs, or clinical laboratory data 21 
(NEM, AJS, HOA-H, CLP, MK, AM and SCK). Blood was procured for immune, 22 
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beginning 10 days after TGN1412 infusion and ending two years post-drug 1 
administration. In parallel, blood samples were obtained from healthy, male volunteers 2 
(n=24; after written informed consent) as comparative controls. All six TGN1412 trial 3 
participants were male, with median age of 29.5 years (range 19-34). The healthy 4 
control volunteers were male, with a median age of 30 years (range 19-42). None of the 5 
patients had a notable medical history and all were well during the two weeks preceding 6 
the clinical trial. Patients B and C were lost to immunological follow-up after 15 and 22 7 
months, respectively. Patients provided written informed consent to data publication. 8 
 9 
Immune monitoring 10 
Immune monitoring started on Day+10 and was continued every 3-4 days for two 11 
weeks, then weekly for four weeks, then every four weeks for three months, and every 12 
six weeks to month eight (time-points 1-17). In the second year, patients were evaluated 13 
every three months (time-points 18-21). For the first six months, whole blood was 14 
assessed for T-cell and dendritic cell (DC) subset numbers, phenotype and function by 15 
measuring intracellular and serum cytokines (Supplemental Fig. 1 and 2). After six 16 
months, tests were rationalized to those that were most informative. Correlates of 17 
immune function or potential were explored, including T-cell receptor Vβ repertoire, 18 
antigen recall assay with purified protein derivative (PPD), and T-cell homing for gut and 19 
skin based on expression of β7 integrin and cutaneous leukocyte antigen (CLA), 20 
respectively. These studies were conducted in a laboratory operating under GLP 21 
principles, undertaking exploratory research and using established protocols that were 22 
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employed were previously validated and tested for performance during the course of 1 
standard general investigative research.  2 
 3 
Flow Cytometry 4 
Whole blood was obtained by venipuncture into sodium-heparin Vacutainer™ 5 
tubes (Becton-Dickinson) and labeled with fluorochrome-conjugated monoclonal 6 
antibodies (mAb; Supplementary Table 1) for surface and intracellular cytokine 7 
detection, as previously described [28], and acquired on a FACSCalibur flow cytometer 8 
using CellQuest software (Becton-Dickinson). The Vβ repertoire kit was kindly donated 9 
by Beckman Coulter. The human FoxP3 staining kit (including anti-FoxP3 mAb; 10 
PCH101-APC) was from eBioscience (cat no.77-5776-40). Analyses were performed 11 
using WinList software (Verity Software House, Maine, USA) using off-line 12 
compensation to ensure objective analysis of data. Absolute cell numbers were 13 
determined by reference to a known quantity of Flow-Count™ Fluorospheres (Beckman 14 
Coulter, cat no. 7547053) added to each aliquot of cells immediately prior to acquisition. 15 
Two DC subsets (Supplementary Fig. 1) and major CD3+ T-cell subsets were 16 
identified (Supplementary Fig. 2). The CD3+/CD8- (hereafter CD3+/CD4+) and 17 
CD3+/CD8+ T-cells were assessed for CD28+/CD25+ subsets, enriched for Tregs. Later 18 
analysis employed a mAb against FoxP3 (in lieu of CD28 mAb) to identify CD3+/CD4+ 19 
Tregs within the CD25+ population. This analysis verified that Tregs identified by 20 
CD28+/CD25+ contained the FoxP3+ subset, despite the absence of high CD25 21 
expression (Supplementary Fig. 2). DC maturation markers (CD80/CD86/CD40) were 22 
not informative and were removed from the protocol after four months (Day+133). At 23 
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allowing for faster laboratory processing of samples (with less cell death), but resulting 1 
in significant disparity in total cell numbers in certain T-cell subsets versus analyses 2 
prior to Day+133 for both the patient and healthy-control samples. 3 
 4 
Cytokine Determinations 5 
All sera (patient and healthy control) were stored at -80°C and thawed for re-6 
aliquoting once prior to assessment. To ensure consistency, cytokines were assessed 7 
on a single run by one operator with a single multi-channel pipette (freshly calibrated) 8 
after a single freeze-thaw cycle for time points 1-19, and then a second run for the last 9 
two time points. Enzyme-linked immunosorbent assay (ELISA) with an ELx808TM 10 
absorbance microplate reader (BioTek Instruments Inc, USA) or a cytokine bead array 11 
was used for quantitative determination of cytokines as per manufacturer’s instructions 12 
(Supplementary Table 2). ELISA determinations were done in duplicate and on different 13 
plates in order to account for plate-to-plate variation. Method controls and normal 14 
control samples were included on each test plate in addition to standard controls for 15 
calibration. Normal controls and method controls were also included in cytokine bead 16 
array with samples tested once.  17 
 18 
Statistical analysis 19 
The statistical analysis was performed by scientists (MK, AM) not involved in 20 
acquisition of data, except for serum cytokine determinations by ELISA, and without 21 
knowledge of clinical outcomes. SigmaStat (Systat Software UK Ltd, London, UK, 22 
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effects of treatment (exposure to TGN1412) on cellular parameters over time within the 1 
patient group and compared with controls. Time-points were only included when data 2 
from all six patients and six controls were available. Two different hypotheses were 3 
tested: 1. whether exposure to TGN1412 affected cytokine levels over time, i.e. patients 4 
vs controls and, 2. whether the numbers of each cell subtype, intracellular cytokine-5 
expressing cells, and level of serum cytokines differed amongst the six patients over 6 
time. The criterion for the implementation of the ANOVA tests was the normality 7 
assumption [29]. Due to the small sample size (no replicates), the homogeneity of 8 
variance, expectedly, was not satisfied only for the second hypothesis. The level of 9 
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Results 1 
The clinical characteristics and recovery of blood counts in the first 30 days 2 
following TGN1412-infusion have been described [26]. Briefly, this 30-day period was 3 
broken down into 4 phases. Phase 1 was the “cytokine storm” starting within an hour of 4 
infusion with rapid induction of type 1 and 2 cytokines, associated with high fever, 5 
severe headache, delirium, nausea, vomiting, diarrhea, diffuse erythema, hypotension, 6 
tachycardia severe lymphopenia and monocytopenia and lasted for 2-3 days. Phase 2 7 
was the “reactive phase”, overlapping with Phase 1 from Day+1 from infusion through 8 
Day+3, and consisted of end-organ damage with renal failure, pulmonary infiltrates, 9 
respiratory failure and disseminated intravascular coagulation. Phase 3 was the 10 
“recovery phase” - renal and pulmonary function normalized, with an accompanying 11 
reactive thrombocytosis, increase in alanine aminotransferase levels, and recovery of 12 
monocyte and lymphocyte counts. This phase started on Day+3 and lasted to Day+15 13 
(or Day+20 in the two sickest patients, C and D, requiring prolonged intensive care). 14 
Phase 4 was the “plateau” or “steady-state” beginning Day+15-20 after TGN1412-15 
infusion and consisted of normalization of blood counts and chemistry panels. During 16 
the first 10-days, all patients displayed generalized desquamation of the skin, muscle 17 
weakness and myalgia which slowly improved [26]. Longer-term effects following 18 
exposure to TGN1412 affected all patients in four main areas: cognitive and psychiatric, 19 
autoimmune and inflammatory, immune mucosal barrier function, and alterations in 20 
immune cell subsets and cytokines in peripheral whole blood (Table 1; Supplementary 21 
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Cognitive and psychiatric effects  1 
The most consistent symptoms in all patients following the SAE were in memory 2 
and concentration (Table 1, Supplementary Table 3 and Supplementary Fig. 3). All 3 
patients reported subjective concentration and day-to-day memory problems, 4 
particularly for names. Although all patients scored within normal range on the Mini 5 
Mental State Examination, bedside cognitive examination and formal neuropsychometry 6 
performed between 6 and 12 months after the SAE revealed common deficits in verbal 7 
recall of information (Supplementary Table 3). Three patients exhibited poor verbal 8 
fluency suggestive of executive dysfunction (Supplementary Table 3). The patients 9 
initially showed some improvement, plateauing approximately 12 months after the event. 10 
These changes, in addition to the SAE itself, generated significant anxiety; 11 
psychotherapy was required in four (Table 1). All patients underwent a comprehensive 12 
psychiatric assessment including a Structured Clinical Interview for Axis I Disorders 13 
(SCID-I). Three patients were diagnosed with mild-to-moderate depression; two of these, 14 
who required a prolonged stay in intensive care, were also diagnosed with post-15 
traumatic stress disorder, (one also had associated panic disorder and agoraphobia; 16 
Table 1). Five patients were able to return to work within two years. However, all noted 17 
that their previous work and everyday capabilities were limited compared with pre-trial 18 
due to decreased concentration, reduced memory and difficulty retaining information, 19 
persisting over two years. 20 
Five patients had intermittent headaches that started several days after stopping 21 
steroids on Days+21-31 and became less frequent in the second year (Table 1; 22 
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affecting the vertex of the head. All patients had unremarkable EEG and brain MRI. Five 1 
patients had normal FDG-PET brain scans (one patient declined). The eldest (patient A), 2 
whose memory and cognitive problems were most severe, had a lumbar puncture one 3 
year post-event which showed oligoclonal bands matched between serum and 4 
cerebrospinal fluid. The patients with headaches also had mild blurred distance vision 5 
(Table 1); in patient C, whose symptoms were most severe, ophthalmologic testing did 6 
not reveal retinal disease or intraocular inflammation, although a change in contrast 7 
sensitivity of vision was noted; he declined further testing. Patient B had mild dry eyes 8 
and blepharitis with hypermetropia. Interestingly, patient D did not have headaches or 9 
blurred vision, yet was the most physically ill, requiring a prolonged stay in intensive 10 
care and a prolonged course of steroids. 11 
 12 
Evidence of autoimmune phenomena and inflammation 13 
Three patients (A, B, F) had mild and intermittent neutropenia, relative to normal 14 
clinical lab reference ranges (Table 1; Fig. 1a). These lower counts were not 15 
accompanied by infection. All patients reported intermittent arthralgias in knees, hands 16 
and back (Table 1; Supplementary Fig. 3). In four, symptoms were associated with low-17 
titer anti-nuclear antibody (ANA; patient D), anti-cardiolipin antibody (ACA; patients A, D, 18 
E, F), intermittent equivocal rheumatoid factor (RF; patient A) or a positive anti-nuclear 19 
cytoplasmic antibody (ANCA) in perinuclear staining pattern directed against PR3 20 
(patient A; also displayed mild neutropenia). These antibodies lasted less than five 21 
months at a time and did not correlate with changes in cell subsets or cytokine 22 
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Patient D was the most physically ill following TGN1412 infusion and suffered 1 
ischemic hands and feet of unclear cause (Table 1; Fig. 2a, b). With improvement in his 2 
overall clinical condition, the extent of ischemia also improved. He underwent bilateral 3 
transmetatarsal amputation and removal of the terminal phalanges of both hands (one 4 
on the right and two on the left). Histopathologic examination showed no features of 5 
primary vasculopathy. The fingers of both hands displayed decreased pigmentation and, 6 
10 months post-infusion, Raynaud’s phenomenon was noted in both hands that 7 
worsened during winter of the second year (18-24 months; Table 1). Autoimmune 8 
antibody testing was consistently negative in this patient except for expression of a 9 
weak anti-nuclear antibody (ANA; 1:40 titer) in speckled pattern at seven and eight 10 
months and a low-titer anti-cardiolipin IgG antibody at eight and 24 months following 11 
infusion.  12 
 13 
Altered mucosal and immune barrier function  14 
Patients A, B and E had new gastrointestinal symptoms (diarrhea or frequent 15 
bowel motions) manifesting as intolerance to spicy foods and associated with a rise of 16 
γδT-cells in the blood (submitted; Table 1 and Supplementary Fig. 3). As the intolerance 17 
improved, this T-cell subset also declined (submitted). Because of the extent of 18 
symptoms in patient B, a full gastrointestinal work-up was undertaken including lactose 19 
intolerance test (normal), esophagogastroduodenoscopy, and colonoscopy; a 5mm 20 
sessile polyp in the proximal ascending colon showed inflammatory change. A cause for 21 
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All patients had skin erythema followed by desquamation to varying degrees and 1 
hair thinning in the days and weeks immediately following TGN1412 infusion. Increased 2 
skin dryness and sensitivity to sun exposure, chemicals and soaps was noted in three 3 
patients (A, C, D; Table 1). Patient B suffered from ongoing pruritus over all skin areas; 4 
cetirizine could not be discontinued over two years due to recurrence of debilitating 5 
symptoms (Table 1 and Supplementary Fig. 3). He had a persistently increased level of 6 
IgE, and intermittent mild eosinophilia without other associated signs or symptoms of 7 
allergy (Fig. 1b, c).  Three other patients (D, E, F) also had persistently elevated IgE, 8 
without specific symptoms or seasonal correlation, two of whom also showed mild 9 
eosinophilia (E, F; Fig. 1b, c). Mast cells were absent from blood and gastrointestinal 10 
biopsies of patient B. Mobile, nontender and rubbery subcutaneous lumps were noted 11 
on the arms, and thorax of patient C (Table 1). Three of these lumps were biopsied on 12 
two occasions, 14 months apart and were found to be benign lipomas or angiolipomas. 13 
Immune cells were not identified in these biopsies and a CT scan did not show 14 
significant adenopathy or lesions elsewhere. 15 
 16 
Recovery kinetics of immune cell subsets and cytokines in peripheral blood 17 
Both CD11c+ conventional and CD11c- plasmacytoid dendritic cells (DCs) were 18 
initially depleted from the blood and recovered slowly over the first month towards 19 
normal (Fig. 3, Supplementary Fig. 4-6, a&b). Peripheral blood monocytes had 20 
recovered to normal by Day+10, unrelated to the recovery kinetics of DCs [26]. Naïve 21 
CD4+ and CD8+ T-cells were detectable in low-to-normal range with a cyclical recovery 22 
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above normal and naïve CD4+ T-cells gradually declined (Fig. 3, Supplementary Fig. 4-1 
6, c&d). Memory CD4+ and CD8+ T-cells were detected at higher-than-normal values 2 
and remained so until 9-12 months post-infusion, followed by a gradual decline in both 3 
to subnormal levels (Fig. 3, Supplementary Fig. 4-6, e&f). Activated CD4+ and CD8+ T-4 
cells were initially high, returned to normal range over six months (Fig. 3, 5 
Supplementary Fig. 4-6, i&j) and followed the recovery pattern of DCs and the slow 6 
decrease of memory T-cells (Supplementary Fig. 7).  7 
TGN1412 was a CD28 superagonist and preclinical studies indicated preferential 8 
stimulation of Tregs. The CD25+/CD28+ T-cell subsets, which include the CD4+ Tregs 9 
and corresponding CD8+ “Treg” population, were in normal range when monitoring 10 
started, decreased to low-to-normal levels over months 1&2 and continued to cycle 11 
circannually within the normal range over the two-year period (Fig. 3, Supplementary 12 
Fig. 4-6, g&h). This circannual cycle was also observed in healthy controls. Interestingly, 13 
the first peak of the CD8+ “Treg” subset occurred three months prior to that of the CD4+ 14 
“Treg” peak, but thereafter cycled together. At 15 months following infusion, the number 15 
of FoxP3+ Tregs was similar to that in healthy controls (data not shown). In vitro 16 
correlates of immune function indicated that T-cell proliferative responses to PPD 17 
antigen presentation, an antigen against which all six patients had previously been 18 
immunized, were similar to that of normal controls at seven months following infusion. 19 
T-cell Vβ repertoires were also normal in the total T-cell populations at 8.6 and 12.1 20 
months following infusion (data not shown). 21 
Despite these similarities, differences in immune cell subsets and cytokines were 22 
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follow-up versus those of the other four patients (Fig. 3; p<0.001), especially regarding 1 
low numbers of CD4+ naïve T-cells and “Tregs” over time. They demonstrated no 2 
clinical similarities beyond those shared with the other patients. Comparison of 3 
intracellular CD4+ and CD8+ T-cell cytokines (spontaneous and stimulated IL-4, IL-10 4 
and IFNγ) indicated that patients B and D were similar to each other and different from 5 
patients A, C, E and F (p<0.001). These patients also shared no unique clinical features 6 
from the other four. Although the clinical relevance of these groupings is currently 7 
unclear, it is notable that patient D, who had several operations and recurrent infections 8 
of his wounds during the two year follow-up, shared similar cellular and cytokine profiles 9 
with those of patients A and B, respectively. These similarities may indicate potentially 10 
common cellular/immune mechanisms underlying different clinical problems found in 11 
these patients. All patients showed a type 1 cytokine skew with significantly higher 12 
intracellular IFNγ production in both CD4+ and CD8+ T-cells upon stimulation (data not 13 
shown). Patient B also had higher serum IFNγ (p<0.001) starting from 2.5 months, and 14 
a different cytokine response in general when compared with that of the other patients 15 
(Fig. 4; p<0.001). He had a sustained increase in erythropoietin from Day+10 following 16 
infusion until three months when IFNγ, IL-1β, IL-12p70, IL-8, IL-4, IL-5 and IL-17 all 17 
started to increase with another peak in these cytokines noted at month nine. He also 18 
had a worsening of his memory and cognitive symptoms and pruritus at month three 19 
following TGN1412 infusion. IL-6, IL-17 and TNFα levels in patients A, D, E and F 20 
increased during the last six months of monitoring, and coincided with declining 21 
CD4+/CD45RA+, CD4+/CD45RO+ and CD8+/CD45RO+ T-cell and Treg numbers during 22 
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Discussion 1 
Intravenous infusion of the CD28 superagonist antibody, TGN1412, resulted in a 2 
cytokine storm heralded by high serum TNFα levels within an hour of infusion, with fever, 3 
delirium, headache, nausea, vomiting and diarrhea, early and rapidly progressive lung 4 
involvement with hypoxemia and disseminated intravascular coagulation. Early 5 
peripheral blood depletion of lymphocytes and monocytes was observed with slow and 6 
specific recovery kinetics, shared by all affected individuals [26]. All volunteers who 7 
received TGN1412 became patients who, on longer-term follow-up, had evidence of 8 
cognitive dysfunction. Some also had psychological difficulties, headaches, autoimmune 9 
and mucosal barrier dysregulation in addition to immune cell subset and cytokine 10 
irregularities in peripheral blood. These features are now recognized in patients treated 11 
with checkpoint blockade and other cancer immunotherapies or in those who have 12 
suffered from CRS. However, it is usually unclear if the irAEs are related to other 13 
premorbid pathology or due to targeting of the underlying disease for which they 14 
required treatment [1, 3-6, 22-24]. In contrast, the significance of the cohort given 15 
TGN1412 is that they were all young and healthy, having been screened extensively for 16 
a first-in-man clinical trial, and had an immune stimulus that resulted in CRS 17 
simultaneously. The patients received similar and concurrent treatment, which enabled 18 
monitoring for irAEs and immunological biomarker assessment for clinical-pathologic 19 
correlation. 20 
The cognitive symptoms were the most consistent feature shared by all patients. 21 
Where psychometric testing was performed, this confirmed initial deficits in recall and 22 
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although headache is now a well-described irAE [9]. The first headaches in all patients 1 
appeared within 90 minutes of infusion, coincident with delirium and an early rise in 2 
TNFα [30, 31]. In pre-clinical testing of TGN1412, specific fibrillary staining was seen in 3 
the cerebrum, cerebellum, spinal cord and pituitary gland of both humans and 4 
cynomolgus monkeys [32]. Since no adverse neurological observations were reported, it 5 
was concluded that this cross-reactivity with central nervous system (CNS) tissues may 6 
not be of major clinical relevance and that TGN1412 was not expected to adversely 7 
affect the CNS in humans. It is unclear whether the described difficulties in cognition 8 
and memory related to specific antibody targeting of the CNS, to the CRS that ensued 9 
[9, 17, 30], to the immune dysregulation that resulted [31, 33], or to the psychological 10 
impact of the events thereafter.  11 
Autoimmune colitis, vitiligo, and autoantibody production are now included in 12 
CTCAE grading of irAEs due to immunotherapy [1, 4, 6, 20, 22, 34]. It is still unknown if 13 
the patients presented here suffered from CRS due to ligation of CD28 on T-cells or 14 
another mechanism, such as monocyte or endothelial activation in the gastrointestinal 15 
tract or lungs, the first organs to be affected after intravenous infusion [11-15]. The 16 
etiology of autoimmune or inflammatory phenomena remains uncertain. It is notable that 17 
following the initial disappearance of blood mononuclear cells (coincident with CRS) 18 
there were different recovery kinetics of monocytes and DCs, consistent with the distinct 19 
lineages of these populations. The Raynaud’s phenomenon in patient D was directly 20 
related to the areas of resolved vascular injury, although the cause of the amelanotic 21 
areas of skin was less clear and may have been autoimmune in nature. Three patients 22 



































































Panoskaltsis et al  
 24 
without evidence of colitis on gut biopsies. All patients had IL-17 levels during immune 1 
reconstitution higher than those of normal controls, and a high level of IgE was found in 2 
four patients. These observations suggest a role for Th17-cells following TGN1412-3 
induced CRS, and are consistent with other reports of irAEs due to immunotherapy [23, 4 
35, 36]. One patient with elevated IgE and debilitating pruritus was distinct in that he 5 
also had marked elevation of type-1 and -2 cytokines starting from three months post-6 
infusion. This cytokine rise coincided with the decline in serum erythropoietin and, in the 7 
setting of hemoglobin levels and renal function similar to those of the other patients, 8 
may have indicated that erythropoietin was immunomodulatory in this setting [37, 38].  9 
The initial appearance of increased activated T-cells and memory subsets was 10 
consistent with generalized immune activation immediately following the cytokine storm. 11 
The relatively few naïve T-cells during early reconstitution is consistent with 12 
programmed recovery in patients following chemotherapy [39, 40], immune checkpoint 13 
blockade [20, 24], or after infection [41, 42]. Contrary to that observed in response to 14 
viral infections and irAEs [20], the immune recovery following TGN1412-induced CRS 15 
was predominantly a CD4+ T-cell response. Since the patients are adults, the increase 16 
in naïve CD8+ T-cells over two years may suggest thymic-independent recovery [39], or 17 
the generation of a stable CD45RA+ memory cell subset from the CD45RO+ pool [43], 18 
also described in patients receiving checkpoint blockade [24]. This latter point may 19 
partially explain declining memory CD45RO+ T-cells over time. However, in light of the 20 
low-to-normal total CD4+ and CD8+ T-cells, this apparent decline could also be 21 
explained by the low point of normal T-cell circannual kinetics at the two-year follow-up 22 
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Over two years, T-cell subsets displayed circannual kinetics [44, 45], especially 1 
noted in the CD25+/CD28+ subsets, incorporating Tregs. The Treg populations were 2 
found in normal numbers in patients relative to control values, and the kinetics of cell 3 
recovery over two years indicates that Treg numbers found in blood or tissues on 4 
single-point testing should be interpreted cautiously. Although TGN1412 was intended 5 
to target Tregs, the Tregs in the patients who received the antibody were normal in 6 
number.  7 
Physical, cognitive and immune abnormalities were observed in previously fit and 8 
healthy young men following infusion of TGN1412. CD28 on T-cells was the intended 9 
antibody target, yet the actual in vivo target in humans after intravenous infusion is 10 
unclear; these human data suggest that primary activation of monocytes or endothelium 11 
in the gut or lung were the primary targets. Clinical-pathologic correlation in these 12 
individuals resulted in valuable observations that may be instructive in understanding 13 
mechanisms of immune-induced pathologies, including those of checkpoint inhibitors, 14 
CAR-T cells, and infections such as COVID-19, known to target mucosal tissues and 15 
cause severe CRS [1, 5, 8, 18, 19]. These observations made in previously healthy 16 
individuals may also provide a template for long-term monitoring strategies that could be 17 
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Figure Legends 1 
 2 
Fig. 1 Two-year follow-up of relevant clinical parameters in the six patients 3 
Absolute neutrophil (a) and eosinophil counts (with values within the first 3 months 4 
highlighted in the panel to the right) (b) followed over the two-year period since 5 
TGN1412-induced cytokine storm show that three of the patients had mild intermittent 6 
neutropenia and three had intermittent eosinophilia. The latter three patients also had 7 
elevated levels of IgE (c), not always correlating with the elevated eosinophil counts. 8 
Horizontal dashed lines indicate the normal control reference ranges for each 9 
parameter. Normal reference ranges were determined for a healthy population in the 10 
clinical pathology accredited hematology laboratory using standard operating 11 
procedures. 12 
Fig. 2 Ischemic and dermatologic changes in Patient D at three months following 13 
TGN1412-induced cytokine storm Areas of dry gangrene became fully demarcated at 14 
two-to-three months following the insult with vascular skin changes in the areas that 15 
became revigorated. Shown are changes prior to amputation of the ischemic digits in 16 
the (a) left hand and (b) right foot. Following amputations, he had persistent pain in both 17 
feet, some of which could be ascribed to phantom-limb pain, and had a sensory deficit 18 
which followed a glove-and-stocking distribution, consistent with the areas originally 19 
affected by ischemia during his critical illness. (c) During the patient’s critical care 20 
phase, an arterial line had been placed in the left radial artery and with recovery, a 21 
hyperkeratotic scar formed, 7cm x 4 cm in maximum dimensions, with faint satellite 22 
amelanotic lesions (1-3mm dimension, arrows). These lesions continued to improve 23 
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Fig. 3 Time course of changes in immune cell subsets during the first two years 1 
following infusion of TGN1412 Ongoing monitoring of T-cell and DC subsets in the 2 
peripheral blood have shown changes over time since the start of the monitoring period, 3 
10 days following infusion of TGN1412. After the four-month time-point, significant 4 
disparity in numbers of certain T-cell subsets was observed, mostly due to shorter 5 
handling times for the samples and a resultant decrease in cell death. The data have 6 
been separated by a vertical dashed line to indicate this change; the entire two-year 7 
monitoring period is shown in a continuous time-course, but with a split in the data after 8 
the four-month change in protocol. The cell subsets measured were: (a) HLA-DR+/Lin-9 
/CD11c+ conventional (“myeloid”) and (b) CD11c- plasmacytoid dendritic cells, (c) 10 
CD45RA+/CD45RO- naive CD4+ helper  and (d) CD8+ cytotoxic T-cells, (e) CD45RA-11 
/CD45RO+ memory CD4+ helper and (f) CD8+ cytotoxic T-cells, CD25+/CD28+ “T-12 
regulatory” CD4+ (g) and CD8+ T-cells (h) and CD69+ activated CD4+ (i) and CD8+ (j) T-13 
cells (with the first four months shown in the inset for clarity of early events). Total CD3+ 14 
T-cells (k) indicates that although the total number of T-cells remained in the normal or 15 
high-normal range, the cell subsets making up the total changed over time. Whereas 16 
naïve CD8+ T-cells remained in the high-normal or higher range at the two-year follow-17 
up, all other T-cells were below normal, especially in memory subsets and 18 
CD25+/CD28+ subsets which included Tregs. However, these low values at the two-year 19 
point were found at the expected trough of the circannual cycling pattern and may be 20 
normal. CD45RA-/CD45RO- T-cells were not observed at any time point during immune 21 
recovery. CD45RA+/CD45RO+ T-cells were observed intermittently throughout recovery 22 
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interquartile ranges for the cohort are shown for each time-point. Median and 1 
interquartile ranges for the normal controls (n=24) drawn at the same time points are 2 
shown separately for the first four months and the remaining 18, indicated by the 3 
horizontal dashed lines on each figure. Total CD3+ (l), CD4+ (m) and CD8+ (n) T-cell 4 
subsets were also evaluated in the clinical laboratory by flow cytometry at the same 5 
time-points and served as an internal control. The total CD3+ cells correlated well 6 
between the research laboratory (k) and the clinical laboratory (l) and the total CD4+ 7 
and CD8+ T-cells remained in the low-normal range over two years.  Conventional units 8 
are shown in the y-axes (cells/mm3 = cells/μl) and is equivalent to 106cells/L in SI units.  9 
Fig. 4 Cytokine levels in patient sera over two years following TGN1412-induced 10 
cytokine storm. Cytokine bead array or ELISA was used to measure cytokines (a) 11 
IFNγ, (b) IL-1β, (c) IL-12p70, (d) IL-8, (e) IL-4, (f) IL-5, (g) IL-17, (h) erythropoietin, (i) 12 
IL-2, (j) IL-10, (k) IL-6, (l) TNFα, (m) IL-11, (n) IL-15, (o) IL-23 and (p) sCD28 in all six 13 
patients for the two-year clinical follow-up. In comparison with the other five patients, 14 
patient B was clearly different in the cytokine response (p<0.001). The level of IL-17 in 15 
the serum of patients over time was found to be different compared with that of matched 16 
controls (p<0.001) and with that of the serum concentrations in the same patients of IL-17 
11, erythropoietin, IL-15, IL-23, sCD28, IFNγ, IL-8, IL-6 and IL-10 (p<0.001). This IL-17 18 
signal suggests a role for cells secreting the cytokine in the immune reconstitution 19 
following cytokine storm. There is no statistical difference between the patient data for 20 
IL-15, IL-11 and IL-23 and those of the normal controls. Statistical comparisons were 21 



































































Table 1. Persistent symptoms and signs over two years following 
TGN1412-induced cytokine storm.  
 
Categories Symptoms and immune correlates  





Memory impairment (6) 
Impairment in attentional processing (6) 
Mild-moderate depression (3) 
Post-traumatic stress disorder  (2) 
Anxiety requiring psychotherapy (4) 
Headaches (5) 










Mild neutropenia (3) 
Arthralgias - knees, hands, back (6) 
Positive auto-antibodies (4) 
Ischemic extremities (1) 








Diarrhea and ↑ γδT cells(3) 
Skin dryness and ↑sensitivity (3) 
Pruritus (1) 
Peripheral blood eosinophilia (3) 
↑ Serum IgE (4) 









Gradual recovery of DC over 1 month (6) 
Low-normal total CD4+ T cells (5) 
1 
1 
Table 1 Click here to access/download;Table;Table 1.doc
cytokines Low-normal total CD8+ T cells (6) 
↑ sustained naïve CD8+ T cells (5) 
↓ naïve CD4+ T cells over time (5) 
↓ memory CD4+ T cells over time (4) 
↓ memory CD8+ T cells over time (4) 
Normal Tregs with circannual cycle (6) 
Vβ repertoire normal (6) 
Normal immune responses in vitro (6) 
↑ sustained erythropoietin level  for 3 
months (1) 
↑ cytokine response from 3 months (1) 













*CTCAE = Common Terminology Criteria for Adverse Events, version 4.03. 
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Clone or catalog number 
γδ-TCRb FITC 11F2 
αβ-TCRb FITC WT31 
CD4  FITC SK3 
CD8  FITC SK1 
CD11c FITC KB90 
CD25  FITC ACT-1 
CD45  FITC 2D1 
CD103  FITC Ber-ACT8 
CD161  FITC DX12 
invariant NKT-cells  FITC 6B11 
NKG2D FITC 1D11 
murine IgG1  FITC X40 
Streptavidin  FITC cat no.554060 
CD3  PE UCHT1 
CD4  PE SK3 
CD8 PE RPA-T8 
CD28  PE L293 
CD45RO PE UCHL1 
CD56  PE MY31 
CD69  PE L78 
CCR5/CD195  PE 2D7 
β7 integrin  PE FIB504 
murine IgG1  PE X40 
murine IgG2a PE G155-178 
rat IgG2a  PE R35-95 
IFN-γ  PE D9D10 
IL-10  PE JES3-9D7 
IL-4  PE MP4-25D2 
CD3 PE-Cy5 UCHT1 
CD8  PE-Cy5 RPA-T8 
CD45RA  PE-Cy5 HI100 
CD45RO  PE-Cy5 UCHL1 
DC exclusion cocktail  PE-Cy5 cat no.MCA2248C 
murine IgG2b  PE-Cy5 27-35 
CD8 PC5 B9.11 
CD4  PerCP  SK3 
CD3b PerCP-Cy5.5 SK7 
CD8  PerCP-Cy5.5 SK1 
CD3  APC UCHT1 
CD4  APC RPA-T4 
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CD8 APC SK1 
CCR9  APC 248621 
HLA-DR APC L243 
murine IgG2a APC 20102 
rat IgG2a  APC 17-4321 
CLA  Biotin HECA-452 
IgM  Biotin R4-22 
 
aAll mAb were purchased from BD Biosciences apart from CD11c-FITC and CD25-FITC 
(Dako), NKG2D-FITC (Abcam), IFNγ-PE, IL-10-PE and IL-4-PE, and dendritic cell 
exclusion cocktail PE-Cy5 (AbD Serotec), CD8-PC5 (Beckman Coulter), rat IgG2a-APC 
(eBioscience), CCR9-APC and murine IgG2a-APC (R&D Systems).  
 
bTCRαβ/γδ/CD3 cocktail was comprised of WT31-FITC, 11F2-PE and SK7-PerCP-Cy5.5.  
 
cFITC: Fluorescein isothiocyanate; PE: Phycoerythrin; PE-Cy5: Phycoerythrin-
Cyanine5.1; PC5: Phycoerythrin-Cyanine5.1; PerCP: Peridinin-chlorophyll-protein 
Complex Conjugate; PerCP-Cy5.5: Peridinin-chlorophyll-protein Complex CY5.5 
Conjugate; APC: Allophycocyanin 
 
Supplementary Table 2. Cytokine determinations, sources and normal reference 
ranges. 
Cytokine Normal Reference 
Range 
Type of Assay / Source 
Erythropoietin (Epo) 3.3-16.6 mIU/ml Quantikine® ELISA Kit; R&D 
Systems Europe Ltd, UK 
IFNγa <27 pg/ml Bead Array; Beckman Coulter 
TNFαa <27 pg/ml Bead Array; Beckman Coulter 
Soluble CD28 (sCD28) 0 pg/ml ELISA; Axxora, UK 
IL-1βa <27 pg/ml Bead Array; Beckman Coulter 
IL-2a <27 pg/ml Bead Array; Beckman Coulter 
IL-4a <27 pg/ml Bead Array; Beckman Coulter 
IL-5a <27 pg/ml Bead Array; Beckman Coulter 
IL-6a <27 pg/ml Bead Array; Beckman Coulter 
IL-8a <14 pg/ml Bead Array; Beckman Coulter 
IL-10a <27 pg/ml Bead Array; Beckman Coulter 
IL-11 <31.2 pg/ml Quantikine® ELISA Kit; R&D 
Systems Europe Ltd, UK 
IL-12p70a <27 pg/ml Bead Array; Beckman Coulter 
IL-15 <3.9 pg/ml, Quantikine® ELISA Kit; R&D 
Systems Europe Ltd, UK 
IL-17 <31.2 pg/ml Quantikine® ELISA Kit; R&D 
Systems Europe Ltd, UK  
IL-23 Unknown ELISA; eBioscience, UK 
 
aTh1/Th2 kit and manifold were a kind gift from Beckman Coulter for the purposes of 
this study. 
Supplementary Table 3. Summary of Psychometric Testing  





















































NT 25-50% 75% 50-75% 
 









aNART = National Adult Reading Test; bVIQ = Verbal Intelligence Quotient; cPIQ = 
Performance Intelligence Quotient; dWRMT = Warrington Recognition Memory Test 
(words); eFRMT = Warrington Recognition Memory Test (faces); fPALT = Paired 
Assocatiate Learning Test; gGNT = Graded Naming Test; hSDMT = Single Digit Modalities 








Supplementary Fig. 1 Gating strategy for peripheral blood conventional 
and plasmacytoid dendritic cells (DCs) Viable whole blood cells (a – R1) 
were used as the starting population to identify HLA-DR+ DCs (b – R2). By 
definition, DCs lack expression of specific cell lineage markers (Lin: CD3, 
CD14, CD16, CD19 and CD34) and are routinely identified based on this 
HLA-DR+/Lin- expression. Relative to an isotype-matched control mAb (c 
inset), both major subsets of peripheral blood DCs could be identified; 








Supplementary Fig. 2 Identification of peripheral blood T-cell subsets by 
four-color flow-cytometry Gating was based on viable whole blood cells (a – 
R1) wherein CD3+ T-cells (b – R2) were identified. Within the CD3+ R2 region, 
gating for absolute numbers of putative CD4+ (c – R3; CD8- cells) and CD8+ 
(c – R4) T-cells was based on the presence or absence of CD8 staining (CD8 
is less susceptible than CD4 to down-regulation during T-cell stimulation used 
in the intracellular cytokine determination protocol [28]) and allowed for two 
more channels to be used for simultaneous positive and negative detection of 
other surface or intracellular proteins. Naïve CD45RA+/CD45RO- (d – R5) and 
memory CD45RA-/CD45RO+ (d – R6) T-cells were identified in each CD8- 
(putative CD4+) and CD8+ T-cell subset (isotype-matched control mAb are 
shown in the insets; d, e and f). Expression of the early activation marker 
CD69 was also quantified on CD4+ and CD8+ subsets of T-cells (e – R7). 
CD4+ and CD8+ populations of CD28+ T-cells were then further analysed for 
expression of CD25, a phenotype associated with regulatory T-cells (f – R8). 
Although Tregs can often be defined by a CD25hi population within the 
CD4+/CD25+ subset, a CD25hi population was not identified, possibly due to 
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Supplementary Fig. 3 
Supplementary Fig. 3 Pictoral diagram of symptoms in the 6 patients during the 2 
year clinical follow-up after infusion of TGN1412 Importance of the symptoms and 
intensity over time were reported subjectively by the patients and documented objectively 
by the lead clinician and are indicated by the width of the bars relative to each other, both 
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Supplementary Fig. 4 Changes in immune cell subsets during the first 4 months 
following infusion of TGN1412 The absolute number of cells relevant to CD28-targeted 
immune therapy was evaluated by flow cytometry in the peripheral blood of patients from 
day+10 following infusion of TGN1412. The cell subsets measured were: (a) HLA-
DR+/Lin-/CD11c+ myeloid and (b) CD11c- plasmacytoid dendritic cells, (c) 
CD45RA+/CD45RO- naïve CD4+ helper  and (d) CD8+ cytotoxic T-cells, (e) CD45RA-
/CD45RO+ memory CD4+ helper and (f) CD8+ cytotoxic T-cells and CD25+/CD28+ “T-
regulatory” CD4+ (g) and CD8+ T-cells (h). Median and interquartile ranges for the cohort 
are shown for each time-point. Median and interquartile ranges for the normal controls 
are indicated by the horizontal dashed lines. Conventional units are shown in the y-axes 
(cells/mm3 = cells/μl) and is equivalent to 106cells/L in SI units. After four months of 
immune monitoring, the tests were rationalized and the patients were evaluated on 2 
separate days, rather than on one day. These changes led to a faster laboratory 
processing time for the samples and resulted in significant disparity in total cell numbers 
measured in certain T-cell subsets only pre- and post-D133 in both the patient and 
healthy-control samples. The graphs depicted here do not display the post-D133 
reference range to depict the changes that resulted (as do the figures for the full 24 month 
follow-up), hence the appearance of a relative increase in the graphed line post-D133, 
which is not of significance. 
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Supplementary Fig. 5 Patient-specific changes in immune cell subsets during the 
first 4 months following infusion of TGN1412 The absolute number of cells relevant 
to CD28-targeted immune therapy was evaluated by flow cytometry in the peripheral 
blood of the 6 affected patients from Day+10 following infusion of TGN1412. The cell 
subsets measured were: (a) HLA-DR+/Lin-/CD11c+ classical and (b) CD11c- 
plasmacytoid dendritic cells, (c) CD45RA+/CD45RO- naïve CD4+ helper  and (d) CD8+ 
cytotoxic T-cells, (e) CD45RA-/CD45RO+ memory CD4+ helper and (f) CD8+ cytotoxic 
T-cells, CD25+/CD28+ “T-regulatory” CD4+ (g) and CD8+ T-cells (h) and CD69+ 
activated CD4+ (i) and CD8+ (j) T-cells. Horizontal medium dashed lines indicate the 1st 
and 3rd quartile of the normal control range, with the horizontal short dashed line 
indicating the median of the normal control range. Conventional units are shown in the 
y-axes (cells/mm3 = cells/μl) and is equivalent to 106cells/L in SI units. After four 
months of immune monitoring, the tests were rationalized and the patients were 
evaluated on 2 separate days, rather than on one day. These changes led to a faster 
laboratory processing time for the samples and resulted in significant disparity in total 
cell numbers measured in certain T-cell subsets only pre- and post-D133 in both the 
patient and healthy-control samples. The graphs depicted here do not display the post-
D133 reference range to depict the changes that resulted (as do the figures for the full 
24 month follow-up), hence the appearance of a relative increase in the graphed line 
post-D133, which is not of significance. 
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Supplementary Fig. 6 Time course of patient-specific changes in immune cell 
subsets during the first 2 years following infusion of TGN1412 The absolute number 
of cells relevant to CD28-targeted immune therapy was evaluated by flow cytometry in 
the peripheral blood of the 6 affected patients from Day+10 following infusion of 
TGN1412. The cell subsets measured were: (a) HLA-DR+/Lin-/CD11c+ classical and (b) 
CD11c- plasmacytoid dendritic cells, (c) CD45RA+/CD45RO- naïve CD4+ helper  and (d) 
CD8+ cytotoxic T-cells, (e) CD45RA-/CD45RO+ memory CD4+ helper and (f) CD8+ 
cytotoxic T-cells, CD25+/CD28+ “T-regulatory” CD4+ (g) and CD8+ T-cells (h) and CD69+ 
activated CD4+ (i) and CD8+ (j) T-cells. Although the total number of CD3+ T-cells (k) 
remained in the normal range for most patients, the cell subsets making up the total 
changed over time. The vertical line at time-point 5 months separates the cell subsets 
affected by the change in protocol – shown are median (horizontal short dashed line) and 
1st and 3rd quartiles (horizontal medium dashed lines) of the normal control range pre and 
post the change. Total CD3+ (l), CD4+ (m) and CD8+ (n) T-cell subsets were also 
evaluated in the clinical laboratory by flow cytometry at the same time-points and served 
as an internal control. The total CD3+ cells correlated well between the research 
laboratory (k) and the clinical laboratory (l) and the total CD4+ and CD8+ T-cells remained 
in the low-normal range for all patients except Patient C over 2 years. Conventional units 







































 T cells  
Naive CD8
+
 T cells 
Memory CD4
+
 T cells 
Memory CD8
+









 T cells 
Activated CD8
+




Supplementary Fig. 7 Representative graph of T-cell subsets following 
TGN1412-induced cytokine storm Absolute number and kinetics of T-cell subsets 
is shown over 2 years, taking into account the change in cell number due to the 
different protocol over the first 4 months of monitoring. Memory CD4+ T-cells are 
greatest in number following the cytokine storm and decrease with time. 
CD8+/CD45RA+ T-cells are maintained at high levels despite the decline of other T-
cell subsets. Conventional units are shown in the y-axes (cells/mm3 = cells/μl) and is 
equivalent to 106cells/L in SI units. 
# Required If available Optional MIATA Sub-Modules
1.1 O Essential donor info
1.2 O Source of cell material
1.3 O Collection methodology
1.4 O       anti-coagulant, if available
1.5 O Transportation/storage conditions for unprocessed samples, if available
1.6 O Cell processing methodology
1.7 O Median time and ranges from sample collection  until end of cell processing, if available
1.8 O       Cut-offs, if used
1.9 O Fresh or cryopreserved
      If cryopreserved
1.10 O           devices used
1.11 O           freezing process
1.12 O           medium used for freezing
1.13 O Median time and temperature for each transportation and storage step, if available
1.14 O       Cut-offs, if used
1.15 O Median cell yield and viability (where available)
1.16 O       before freezing
1.17 O       after thawing
1.18 O       after overnight resting
1.19 O       Cut-offs, if used
1.20 O Cell counting methodology
1.21 O Optional: Additional assessments
2.1 O Medium/(serum) details
2.2 O Pretesting info
2.3 O Treatment procedures of cells prior to assay, if applicable
2.4 O Sufficient assay details
2.5 O Internal assay controls
2.6 O       Acceptance criteria, if available
2.7 O External reference samples, if used
2.8 O       Assay acceptance criteria, if available
3.1 O Equipment and software version
3.2 O Basic equipment settings, if available
3.3 O Detailed gating strategy or strategy for establishing spot detection parameters
3.4 O Representative data set
3.5 O Mean,median, ranges of event counts for relevant populations, if available
3.6 O Optional: Unusual strategies explained
3.7 O Optional: Review of raw data
4.1 O Background and ag-specific reactivity levels, if available
4.2 O       Cut-off specifications and # of tests OOS, if available
4.3 O Accessibility of raw data addressed?
4.4 O Definition of positive reactivity (above background) including tests applied
4.5 O Parameters, software and version used for response determination, if applicable
4.6 O Response definition predefined or post-hoc?
4.7 O Definition of response induced by treatment, if applicable
4.8 O Any data excluded and why, if applicable?
4.9 O Optional: Why test was used
5.1 O Guidance of lab operations
5.2 O Laboratory accreditions and certifications, if available
5.3 O Optional: Details on audits
5.4 O Status of protocols
5.5 O Status of assays
5.6 O Optional: Specific performance criteria
Module 3B - Acquisition Strategy and Gating
Module 2 - Assay
Module 2A - Medium/serum
Module 2B - Assay
Module 2C - Controls
Module 3 - Data Acquisition
Module 3A - Equipment and software
Module 5C - Qualification/Validation
Module 4 - Results
Module 4A - Raw data
Module 4B - Response determination
Module 5
Module 5A - General Lab Operation
Module 5B - Standardization
Module 1 - Sample
Module 1A - Donor
Module 1B Source
Module 1C - Cryopreservation and Storage
Module 1D - Cell Counting
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